Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2023 financial results on May 4, 2023, at 8:30 a.m. Eastern Time. The company will also provide a corporate update during a webcast, which will be available on its website. Liquidia is focused on developing treatments for pulmonary hypertension and has developed YUTREPIA™, an investigational inhalation powder for pulmonary arterial hypertension (PAH), which received tentative FDA approval in November 2021. For further information, a rebroadcast of the webcast will be available for 30 days following the live event.
Liquidia Corporation (NASDAQ: LQDA) has announced that CFO Michael Kaseta will present a business overview during a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference. The session is scheduled for April 18, 2023, at 11:00 a.m. Eastern Standard Time.
Interested participants can access the live webcast on Liquidia's website, and an archived version will be available for 30 days post-event. Liquidia focuses on developing treatments for pulmonary hypertension and uses its proprietary PRINT® Technology. The company’s investigational product, YUTREPIA™, is aimed at treating pulmonary arterial hypertension.
Liquidia Corporation (NASDAQ: LQDA) announced a new, non-exclusive license agreement with GSK, replacing a prior collaboration from 2012. This agreement allows Liquidia to leverage its PRINT® technology for developing inhaled formulations, excluding certain GSK proprietary molecules. GSK retains a non-exclusive, royalty-free right for pre-clinical research. CEO Roger Jeffs highlighted benefits from restructuring the relationship to enhance product development opportunities. The earlier agreement had granted GSK an exclusive license in inhaled therapeutics, but the new terms require GSK to seek an expanded license for clinical or commercial use.
Liquidia Corporation (NASDAQ: LQDA) reported a net loss of $41 million for the full year ending December 31, 2022, with a revenue increase to $15.9 million from $12.9 million in 2021. The decrease in profit-sharing from its agreement with Sandoz, which fell from 80% to 50%, was countered by an increase in units sold. The company clarified its path to launching YUTREPIA, anticipating legal resolution by mid-2024, and has strengthened its financial position through various financing activities, including a $100 million revenue interest deal. The company's cash reserves increased to $93.3 million.
Liquidia Corporation (NASDAQ: LQDA) will announce its full-year 2022 financial results on March 16, 2023. A live webcast is scheduled for 8:30 a.m. Eastern Time, where the company will discuss its financial outcomes and provide a corporate update.
Liquidia is a biopharmaceutical firm focusing on pulmonary hypertension treatments, utilizing its PRINT® Technology. Its YUTREPIA™ inhalation powder has received tentative FDA approval for pulmonary arterial hypertension (PAH), indicating progress in its product development.